HALF YEAR RESULTS 2022

Andreas Eckert, CEO

11 August 2022

1

A Diversified Global Specialist for Radioactive Applications

ISOTOPE

PRODUCTS

Industry

Radiation

Sources

Services

Trade

Disposal

MEDICAL

Medicine

Medical Devices

Pharmaceuticals

Lab Devices

Engineering

Others

Group Items/

Pipeline

Holding

Pentixa

Myelo

Special projects

Engine

+++

106.8 million EUR Revenues in Q2 2022

2

15.4 million EUR Net Income

957 Employees (Headcounts)

19 Sites Worldwide

Results Q2-2022

(EUR million)

Since January 3rd, 2022

Tecnonuclear

3 Buenos Aires

Revenues

106.8

Net Income

15.4

NI/ Sales = 14%

2%

9%

43%

46%

America

Europe

Asia

Middle East & Africa

Slides only for illustration - the spoken word shall be binding

Growing Profits,

Growing Dividends

Dividend/ share in EUR

(share splitt adjusted)

Net Income in mm EUR

x 2,5

x 2,4

4

In the Middle of an Expanding Specialty Pharma Market

5

Um den Rest dieser Noodl zu lesen, rufen Sie bitte die Originalversion auf, und zwar hier.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Eckert & Ziegler AG published this content on 11 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2022 17:11:06 UTC.